Last 15 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | 20.01 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 2.86 | 1.60 | 1.66 | 1.73 | 1.87 | 1.88 | 0.76 | 0.93 | 0.52 | 0.60 | 0.83 | 1.08 | 1.64 | — | — | — |
| — | -15.0% | +120.1% | +85.9% | +258.0% | +216.5% | -8.8% | -14.1% | -68.1% | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | -372.6% | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | -317.6% | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -38.2% | -7.8% | -10.0% | -8.3% | -10.4% | -7.7% | -12.3% | -9.9% | -8.3% | -4.3% | -4.7% | -8.6% | -6.5% | — | -30.0% | — |
| — | -0.8% | +19.2% | +16.4% | -25.3% | -77.4% | -161.4% | -15.0% | -27.3% | — | +84.3% | — | — | — | — | — | |
| ROA | -36.9% | -7.5% | -9.5% | -7.8% | -9.7% | -7.3% | -11.9% | -9.7% | -8.0% | -4.2% | -4.6% | -8.2% | -10.2% | -27.8% | -21.9% | -21.8% |
| — | -2.6% | +19.9% | +19.2% | -20.8% | -73.0% | -160.6% | -18.4% | +21.3% | +84.8% | +79.2% | +62.5% | — | — | — | — | |
| ROIC | -54.5% | -15.0% | -12.3% | -9.9% | -12.3% | -11.0% | -19.3% | -15.7% | -14.0% | -15.8% | -45.0% | -117.1% | — | — | — | — |
| — | -36.2% | +36.0% | +37.0% | +12.1% | +30.1% | +57.1% | +86.6% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.01 | — |
| — | +548.5% | +35.6% | +39.7% | +41.8% | +39.9% | +105.1% | -29.8% | -35.4% | — | -98.3% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 22.82 | 45.02 | 20.34 | 22.82 | 13.04 | 17.55 | 20.34 | 34.30 | 38.41 | 29.11 | 43.12 | 17.09 | 20.36 | 4.04 | 5.12 | 6.21 |
| — | +156.5% | -0.0% | -33.5% | -66.1% | -39.7% | -52.8% | +100.7% | +88.6% | +620.8% | +742.9% | +175.2% | — | — | — | — | |
| Quick Ratio | 22.82 | 45.02 | 20.34 | 22.82 | 13.04 | 17.55 | 20.34 | 34.30 | 38.41 | 29.11 | 43.12 | 17.09 | 20.36 | 4.04 | 5.12 | 6.21 |
| — | +156.5% | -0.0% | -33.5% | -66.1% | -39.7% | -52.8% | +100.7% | +88.6% | +620.8% | +742.9% | +175.2% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SGMT stock.
Sagimet Biosciences Inc.'s current P/E is -11.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sagimet Biosciences Inc.'s business trajectory between earnings reports.